不同剂量多奈哌齐对阿尔茨海默病患者认知功能及血清IGF-1水平的影响  

Effects of different doses of donepezil on cognitive function and serum IGF-1 level in patients with Alzheimer's disease

作　　者：宋宇[1] 方堃[1] 杨文君[2] 周云竹 SONG Yu;FANG Kun;YANG Wenjun;ZHOU Yunzhu(Sichuan Provincial Science City Hospital,Mianyang,Sichuan 621000,China;Sichuan Provincial Mental Health Center,Mianyang,Sichuan 621000,China)

机构地区：[1]四川省科学城医院,四川绵阳621000 [2]四川省精神卫生中心,四川绵阳621000

出　　处：《检验医学与临床》2020年第6期761-764,共4页Laboratory Medicine and Clinic

基　　金：四川省卫生和计划生育委员会基金项目(16PJ402);西部精神医学协会公益基金项目(wcpafund2014-12)。

摘　　要：目的探讨不同剂量多奈哌齐对阿尔茨海默病(AD)患者认知功能与血清胰岛素样生长因子-1(IGF-1)水平的影响。方法选取四川省科学城医院2016年9月至2017年8月收治的AD患者96例为研究对象,按照随机数字表法分为低剂量组、中剂量组、高剂量组3组,每组32例。低剂量组每次口服2.5 mg多奈哌齐,中剂量组每次口服5.0 mg多奈哌齐,高剂量组每次口服10.0 mg多奈哌齐。比较3组患者治疗前,治疗后3、6、9个月的简易精神状态量表(MMSE量表)、阿尔茨海默病评定量表认知分量表(ADAS-cog量表)评分及血清IGF-1水平。结果低剂量组治疗前与治疗后3、6、9个月的MMSE量表评分、ADAS-cog量表评分、IGF-1水平比较,差异均无统计学意义(P>0.05)。中剂量组与高剂量组治疗后6、9个月的MMSE量表评分、ADAS-cog量表评分、IGF-1水平与治疗前比较,差异均有统计学意义(P<0.05),且高剂量组治疗后6、9个月的MMSE量表评分、IGF-1水平高于中剂量组、低剂量组,ADAS-cog量表评分低于中剂量组、低剂量组,差异均有统计学意义(P<0.05)。结论多奈哌齐可显著改善AD患者认知功能、提升日常生活能力和升高血清IGF-1水平,且存在剂量相关效应,高剂量多奈哌齐疗效更佳。Objective To investigate the effects of different doses of donepezil on the cognitive function and serum insulin-like growth factor-1(IGF-1)in the patients with Alzheimer's disease(AD).Methods Ninety-six patients with AD admitted to Sichuan Provincial Science City Hospital from September 2016 to August 2017 were selected as the study subjects and divided into the low dose group,middle dose group and high dose group according to the random number table method,32 cases in each group.The low dose group took oral 2.5 mg donepezil each time,the middle dose group took oral 5.0 mg donepezil each time and the high dose group received oral 10.0 mg donepezil each time.The Mini Mental State Scale(MMSE scale),the Alzheimer's disease Assessment Scale-cognitive Subscale scale(ADAS-cog scale)and serum IGF-1 level before treatment,in 3,6,9 months after treatment were compared among the three groups.Results The MMSE scale score,ADAS-cog scale score and IGF-1 level in the low dose group had no statistical differences between before treatment and in 3,6,9 months after treatment(P>0.05).The MMSE scale score,ADAS-cog scale score and IGF-1 level in the middle dose group and the high dose group had statistical differences between before treatment and in 6,9 months after treatment(P<0.05),moreover the scores of MMSE scale and IGF-1 levels in 6,9 months after treatment in the high dose group were higher than those in the middle dose group and the low dose group,the ADAS-cog scale score was lower than that in the middle dose group and the low dose group,and the differences were statistically significant(P<0.05).Conclusion Donepezil can significantly improve the cognitive function,increase the daily living ability and serum IGF-1 level in the patients with AD,moreover the dose related effect exists,and the curative effect of high dose donepezil is better.

关 键 词：多奈哌齐 阿尔茨海默病 认知功能 胰岛素样生长因子-1 

分 类 号：R745.7[医药卫生—神经病学与精神病学]